Abrunhosa, Antero
Claim profile
Loading...
2
0
20
0
false
Credit Name
Abrunhosa, Antero
Name
Abrunhosa, Antero
Variants
Abrunhosa, Antero J.
Unidade de I&D
Ciência ID
Scopus Author ID
Status
UC Researcher
Biography
First degree in Biochemistry (1992) and MSc in Biomedical Engineering (1996) from the University of Coimbra, Portugal. PhD work under Prof. Terry Jones’ supervision at the MRC - Cyclotron Unit, Hammersmith Hospital in London, UK (2002). From 2000 to 2009, helped to design and supervised the construction of the Institute for Nuclear Sciences Applied to Health (ICNAS) a leading facility in Portugal for Nuclear Imaging based at the University of Coimbra. He is the current Director of the Institute and the head of the Radiochemistry Laboratory (RCL). ICNAS has extensive expertise in the development of radiopharmaceuticals for Oncology, Cardiology and Neuroscience and is fully equipped for clinical imaging (2 PET/CT and a 3T MR) as well as pre-clinical studies (including an in-house developed world leading high-resolution small animal PET with 0.3 mm resolution, a 9.4T micro-MRI, an optical imaging system and a photoacoustic tomography device). The RCL hosts 2 cyclotrons (IBA cyclone 18/9 and the first IBA Kiube variable energy, installed in 2019) and is fully licensed as a GMP manufacturing site, currently producing more than 20 different tracers based on 11C, 13N, 18F, 68Ga, 61Cu and 64Cu. The facility is the main supplier of PET radiopharmaceuticals for Portugal, through its subsidiary (ICNAS-P, a company fully owned by the University) that currently has 6 radiopharmaceuticals in the market (FDG, FCH, NaF, 68Ga-DOTANOC, 68Ga-PSMA-11 and F-DOPA). Antero is manager and Head of Production for ICNAS-P from the start. Antero’s research interests include development of targeted probes for molecular imaging, PET, SPECT, radiopharmaceutical development, PET Radiopharmacy and Quality Control, pre-clinical imaging and clinical trials. The Institute is currently participating in more than 30 clinical trials and has recently received approval, by the authorities, of its first investigator driven clinical trial. Regarding technology transfer, Antero promoted the start of 3 spin-off companies from the University of Coimbra, one of them (Fluidomica, Lda) specializes in supplying target solutions for radiometal production. He is a member of the European Pharmacopoeia Group 14 and an Expert in several Technical Committees and Field Missions for IAEA (International Atomic Energy Agency). He currently holds patents in Europe, US and Japan regarding the production of gallium-68 using liquid targets.
Loading...
3
0
20
0
false